Xuanzhu Biopharmaceutical Co., Ltd. Class H

As of December 31, 2025, Xuanzhu Biopharmaceutical Co., Ltd. Class H carries a market capitalization of 36.52B, placing it among publicly traded companies globally. Its enterprise value stands at 35.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Xuanzhu Biopharmaceutical Co., Ltd. Class H has 517.95M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 568.76, and the price-to-book ratio stands at 23.95.

These figures are as of December 31, 2025. The EV/Sales ratio of 621.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 35.79B versus a market cap of 36.52B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Xuanzhu Biopharmaceutical Co., Ltd. Class H maintains a current ratio of 3.75, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.05, indicating conservative leverage, while an interest coverage ratio of -1,587.18 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. The company generates approximately 168,469.53 in revenue per employee across its workforce of 342.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended December 31, 2025, Xuanzhu Biopharmaceutical Co., Ltd. Class H recorded 6,677.34 in income tax expense. The company reported a pretax loss of -273.22M and -273.22M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Xuanzhu Biopharmaceutical Co., Ltd. Class H's stock has declined approximately 86.17% over the past 52 weeks. The 50-day moving average sits at 9.53, while the 200-day moving average is 28.58.

Over the twelve months ended December 31, 2025, Xuanzhu Biopharmaceutical Co., Ltd. Class H generated 57.62M in revenue and converted that into -273.22M in net income, yielding earnings per share of -0.59. EBITDA reached -219.03M, while operating income came in at -241.54M.

As of December 31, 2025, Xuanzhu Biopharmaceutical Co., Ltd. Class H holds 725.86M in cash and equivalents against 720,040.33 in total debt, resulting in a net debt position of -725.86M. Total book value stands at 1.52B, with working capital of 679.55M providing operational flexibility.

Xuanzhu Biopharmaceutical Co., Ltd. Class H produced -233.66M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -47.37M in capital expenditures, free cash flow totaled -281.03M - equivalent to -0.60 per share.

Over the twelve months ended December 31, 2025, Xuanzhu Biopharmaceutical Co., Ltd. Class H posted a gross margin of 64.45, reflecting its pricing power and cost economics. The operating margin of -419.21 and net profit margin of -474.21 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -0.86: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.90, meaning Xuanzhu Biopharmaceutical Co., Ltd. Class H raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2025, Xuanzhu Biopharmaceutical Co., Ltd. Class H has an Altman Z-Score of 69.64, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.